IL323682A - שיטות ותכשירים להפחתת הסימפטומים של מחלת פרקינסון - Google Patents

שיטות ותכשירים להפחתת הסימפטומים של מחלת פרקינסון

Info

Publication number
IL323682A
IL323682A IL323682A IL32368225A IL323682A IL 323682 A IL323682 A IL 323682A IL 323682 A IL323682 A IL 323682A IL 32368225 A IL32368225 A IL 32368225A IL 323682 A IL323682 A IL 323682A
Authority
IL
Israel
Prior art keywords
daily
baseline
time
hours
reduction
Prior art date
Application number
IL323682A
Other languages
English (en)
Inventor
Liat Adar
Nelson Felix Lopes
Laurence Salin
Tamar Yardeni
Nissim Sasson
Sheila Oren
Hikari Yarita
Mikio Himizu
Natalia Vostokova
Original Assignee
Neuroderm Ltd
Liat Adar
Nelson Felix Lopes
Laurence Salin
Tamar Yardeni
Nissim Sasson
Sheila Oren
Hikari Yarita
Mikio Himizu
Natalia Vostokova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroderm Ltd, Liat Adar, Nelson Felix Lopes, Laurence Salin, Tamar Yardeni, Nissim Sasson, Sheila Oren, Hikari Yarita, Mikio Himizu, Natalia Vostokova filed Critical Neuroderm Ltd
Publication of IL323682A publication Critical patent/IL323682A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL323682A 2023-04-14 2025-09-29 שיטות ותכשירים להפחתת הסימפטומים של מחלת פרקינסון IL323682A (he)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363459438P 2023-04-14 2023-04-14
US202363508634P 2023-06-16 2023-06-16
US202318234232A 2023-08-15 2023-08-15
US202463564464P 2024-03-12 2024-03-12
PCT/IL2024/050368 WO2024214102A1 (en) 2023-04-14 2024-04-14 Methods and compositions for reducing symptoms of parkinson's disease

Publications (1)

Publication Number Publication Date
IL323682A true IL323682A (he) 2025-11-01

Family

ID=93058963

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323682A IL323682A (he) 2023-04-14 2025-09-29 שיטות ותכשירים להפחתת הסימפטומים של מחלת פרקינסון

Country Status (6)

Country Link
CN (1) CN120936350A (he)
AU (1) AU2024250257A1 (he)
IL (1) IL323682A (he)
MX (1) MX2025012236A (he)
TW (1) TW202448421A (he)
WO (1) WO2024214102A1 (he)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11213502B1 (en) * 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
EP4223288B1 (en) * 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease

Also Published As

Publication number Publication date
TW202448421A (zh) 2024-12-16
WO2024214102A1 (en) 2024-10-17
MX2025012236A (es) 2025-11-03
AU2024250257A1 (en) 2025-11-27
CN120936350A (zh) 2025-11-11

Similar Documents

Publication Publication Date Title
IL266648A (he) שיטה לטיפול במחלת פרקינסון
IL295308A (he) שיטות לטיפול ביתר שינה אידיופטית
JP2023171776A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2018184440A (ja) うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
CN1938010B (zh) 肽化合物在疼痛性糖尿病神经病变中治疗疼痛的用途
US20200113883A1 (en) Durable treatment with 4-aminopyridine in patients with demyelination
US20190328719A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine
IL297642A (he) שיטות לשימוש במאפנני תעלת סידן מסוג t
IL279220B2 (he) שימוש של (s)-3-אמינו-4-(דיפלואורומתילניל)ציקלופנט-1-אן-1-חומצה קרבוקסילית ותרכובות קשורות, (1s, 3s)-3-אמינו-4-(דיפלואורומתילידן)ציקלופנטאן-1-חומצה קרבוקסילית וויגאבטרין בטיפול בהפרעות התפתחותיות
IL323682A (he) שיטות ותכשירים להפחתת הסימפטומים של מחלת פרקינסון
IL277553B2 (he) תכשירים לטיפול במחלות נוירודגנרטיביות ע" י מתן רציף
US12161612B2 (en) Methods and compositions for reducing symptoms of Parkinson's disease
CA3243616A1 (en) TREATMENT METHODS USING T-TYPE CALCIUM CHANNEL MODULATORS
KR20260009826A (ko) 파킨슨병의 증상을 감소시키기 위한 방법 및 조성물
HK1173911B (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with multiple sclerosis